bp single-end sequencing Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 80
    Illumina Inc bp single end sequencing
    Bp Single End Sequencing, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 80/100, based on 8 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bp single end sequencing/product/Illumina Inc
    Average 80 stars, based on 8 article reviews
    Price from $9.99 to $1999.99
    bp single end sequencing - by Bioz Stars, 2020-01
    80/100 stars
      Buy from Supplier

    87
    Illumina Inc hiseq single end 50 bp sequencing
    Hiseq Single End 50 Bp Sequencing, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 87/100, based on 12 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hiseq single end 50 bp sequencing/product/Illumina Inc
    Average 87 stars, based on 12 article reviews
    Price from $9.99 to $1999.99
    hiseq single end 50 bp sequencing - by Bioz Stars, 2020-01
    87/100 stars
      Buy from Supplier

    87
    Illumina Inc 100 bp single end sequencing
    A pooled screen for functional validation of CLD. a The screening strategy in SW480 cells. In brief, a pool of mutant SW480 cells harboring 12,471 sgRNA designs against 408 genes was generated by lentiviral infection and antibiotic selection. Fourteen million cells per condition were then treated with PBS (control) or recombinant TRAIL (treatment) for a total of 12 days. Subsequently, the genomic DNA of the samples was extracted and sgRNA composition analyzed by next-generation sequencing ( NGS ). b Comparison of sgRNA sequence counts between two biological replicates demonstrates high reproducibility (Pearson correlation coefficient ~0.79). c Distribution of sgRNAs targeting positive pathway regulators ( CASP8 , CASP3 , FADD , BAX , BID , TNFRSF10A , TNFRSF10B ) in red , negative regulators ( XIAP , BCL2L1 ) in blue , and random, non-targeting sgRNAs in orange between TRAIL ( y-axis ) and PBS ( x-axis ) treated cell populations. d Scatter plot showing relative enrichment of genes ( y-axis ) with their corresponding p value ( x-axis ). Positive regulators are plotted in red , negative regulators in blue , and random, non-targeting sgRNAs in orange. P values were calculated by Wilcoxon rank sum test between 30 sgRNAs of one gene and 200 random, non-targeting sgRNAs. Log 2 fold change is calculated as median log 2 ratio between normalized sgRNA count of TRAIL- over PBS-treated populations. The vertical line marks a p value of 0.05. e – g Median normalized fold change of all sgRNAs targeting three essential TRAIL pathway components. A total of <t>100</t> sgRNAs are depicted for each gene. Enriched sgRNAs are colored in red , depleted sgRNAs in grey . The dashed line represents the median fold change of all sgRNAs of the corresponding gene
    100 Bp Single End Sequencing, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 87/100, based on 26 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/100 bp single end sequencing/product/Illumina Inc
    Average 87 stars, based on 26 article reviews
    Price from $9.99 to $1999.99
    100 bp single end sequencing - by Bioz Stars, 2020-01
    87/100 stars
      Buy from Supplier

    82
    Illumina Inc hiseq 4000 single ended 50 bp sequencing
    A pooled screen for functional validation of CLD. a The screening strategy in SW480 cells. In brief, a pool of mutant SW480 cells harboring 12,471 sgRNA designs against 408 genes was generated by lentiviral infection and antibiotic selection. Fourteen million cells per condition were then treated with PBS (control) or recombinant TRAIL (treatment) for a total of 12 days. Subsequently, the genomic DNA of the samples was extracted and sgRNA composition analyzed by next-generation sequencing ( NGS ). b Comparison of sgRNA sequence counts between two biological replicates demonstrates high reproducibility (Pearson correlation coefficient ~0.79). c Distribution of sgRNAs targeting positive pathway regulators ( CASP8 , CASP3 , FADD , BAX , BID , TNFRSF10A , TNFRSF10B ) in red , negative regulators ( XIAP , BCL2L1 ) in blue , and random, non-targeting sgRNAs in orange between TRAIL ( y-axis ) and PBS ( x-axis ) treated cell populations. d Scatter plot showing relative enrichment of genes ( y-axis ) with their corresponding p value ( x-axis ). Positive regulators are plotted in red , negative regulators in blue , and random, non-targeting sgRNAs in orange. P values were calculated by Wilcoxon rank sum test between 30 sgRNAs of one gene and 200 random, non-targeting sgRNAs. Log 2 fold change is calculated as median log 2 ratio between normalized sgRNA count of TRAIL- over PBS-treated populations. The vertical line marks a p value of 0.05. e – g Median normalized fold change of all sgRNAs targeting three essential TRAIL pathway components. A total of <t>100</t> sgRNAs are depicted for each gene. Enriched sgRNAs are colored in red , depleted sgRNAs in grey . The dashed line represents the median fold change of all sgRNAs of the corresponding gene
    Hiseq 4000 Single Ended 50 Bp Sequencing, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 82/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hiseq 4000 single ended 50 bp sequencing/product/Illumina Inc
    Average 82 stars, based on 6 article reviews
    Price from $9.99 to $1999.99
    hiseq 4000 single ended 50 bp sequencing - by Bioz Stars, 2020-01
    82/100 stars
      Buy from Supplier

    82
    Illumina Inc hiseq2500 single end 100 bp sequencing lane
    A pooled screen for functional validation of CLD. a The screening strategy in SW480 cells. In brief, a pool of mutant SW480 cells harboring 12,471 sgRNA designs against 408 genes was generated by lentiviral infection and antibiotic selection. Fourteen million cells per condition were then treated with PBS (control) or recombinant TRAIL (treatment) for a total of 12 days. Subsequently, the genomic DNA of the samples was extracted and sgRNA composition analyzed by next-generation sequencing ( NGS ). b Comparison of sgRNA sequence counts between two biological replicates demonstrates high reproducibility (Pearson correlation coefficient ~0.79). c Distribution of sgRNAs targeting positive pathway regulators ( CASP8 , CASP3 , FADD , BAX , BID , TNFRSF10A , TNFRSF10B ) in red , negative regulators ( XIAP , BCL2L1 ) in blue , and random, non-targeting sgRNAs in orange between TRAIL ( y-axis ) and PBS ( x-axis ) treated cell populations. d Scatter plot showing relative enrichment of genes ( y-axis ) with their corresponding p value ( x-axis ). Positive regulators are plotted in red , negative regulators in blue , and random, non-targeting sgRNAs in orange. P values were calculated by Wilcoxon rank sum test between 30 sgRNAs of one gene and 200 random, non-targeting sgRNAs. Log 2 fold change is calculated as median log 2 ratio between normalized sgRNA count of TRAIL- over PBS-treated populations. The vertical line marks a p value of 0.05. e – g Median normalized fold change of all sgRNAs targeting three essential TRAIL pathway components. A total of <t>100</t> sgRNAs are depicted for each gene. Enriched sgRNAs are colored in red , depleted sgRNAs in grey . The dashed line represents the median fold change of all sgRNAs of the corresponding gene
    Hiseq2500 Single End 100 Bp Sequencing Lane, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 82/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hiseq2500 single end 100 bp sequencing lane/product/Illumina Inc
    Average 82 stars, based on 6 article reviews
    Price from $9.99 to $1999.99
    hiseq2500 single end 100 bp sequencing lane - by Bioz Stars, 2020-01
    82/100 stars
      Buy from Supplier

    82
    Illumina Inc hiseq 2500 51 bp single end sequencing
    A pooled screen for functional validation of CLD. a The screening strategy in SW480 cells. In brief, a pool of mutant SW480 cells harboring 12,471 sgRNA designs against 408 genes was generated by lentiviral infection and antibiotic selection. Fourteen million cells per condition were then treated with PBS (control) or recombinant TRAIL (treatment) for a total of 12 days. Subsequently, the genomic DNA of the samples was extracted and sgRNA composition analyzed by next-generation sequencing ( NGS ). b Comparison of sgRNA sequence counts between two biological replicates demonstrates high reproducibility (Pearson correlation coefficient ~0.79). c Distribution of sgRNAs targeting positive pathway regulators ( CASP8 , CASP3 , FADD , BAX , BID , TNFRSF10A , TNFRSF10B ) in red , negative regulators ( XIAP , BCL2L1 ) in blue , and random, non-targeting sgRNAs in orange between TRAIL ( y-axis ) and PBS ( x-axis ) treated cell populations. d Scatter plot showing relative enrichment of genes ( y-axis ) with their corresponding p value ( x-axis ). Positive regulators are plotted in red , negative regulators in blue , and random, non-targeting sgRNAs in orange. P values were calculated by Wilcoxon rank sum test between 30 sgRNAs of one gene and 200 random, non-targeting sgRNAs. Log 2 fold change is calculated as median log 2 ratio between normalized sgRNA count of TRAIL- over PBS-treated populations. The vertical line marks a p value of 0.05. e – g Median normalized fold change of all sgRNAs targeting three essential TRAIL pathway components. A total of <t>100</t> sgRNAs are depicted for each gene. Enriched sgRNAs are colored in red , depleted sgRNAs in grey . The dashed line represents the median fold change of all sgRNAs of the corresponding gene
    Hiseq 2500 51 Bp Single End Sequencing, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 82/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hiseq 2500 51 bp single end sequencing/product/Illumina Inc
    Average 82 stars, based on 6 article reviews
    Price from $9.99 to $1999.99
    hiseq 2500 51 bp single end sequencing - by Bioz Stars, 2020-01
    82/100 stars
      Buy from Supplier

    82
    Solexa 160 bp single end sequencing
    A pooled screen for functional validation of CLD. a The screening strategy in SW480 cells. In brief, a pool of mutant SW480 cells harboring 12,471 sgRNA designs against 408 genes was generated by lentiviral infection and antibiotic selection. Fourteen million cells per condition were then treated with PBS (control) or recombinant TRAIL (treatment) for a total of 12 days. Subsequently, the genomic DNA of the samples was extracted and sgRNA composition analyzed by next-generation sequencing ( NGS ). b Comparison of sgRNA sequence counts between two biological replicates demonstrates high reproducibility (Pearson correlation coefficient ~0.79). c Distribution of sgRNAs targeting positive pathway regulators ( CASP8 , CASP3 , FADD , BAX , BID , TNFRSF10A , TNFRSF10B ) in red , negative regulators ( XIAP , BCL2L1 ) in blue , and random, non-targeting sgRNAs in orange between TRAIL ( y-axis ) and PBS ( x-axis ) treated cell populations. d Scatter plot showing relative enrichment of genes ( y-axis ) with their corresponding p value ( x-axis ). Positive regulators are plotted in red , negative regulators in blue , and random, non-targeting sgRNAs in orange. P values were calculated by Wilcoxon rank sum test between 30 sgRNAs of one gene and 200 random, non-targeting sgRNAs. Log 2 fold change is calculated as median log 2 ratio between normalized sgRNA count of TRAIL- over PBS-treated populations. The vertical line marks a p value of 0.05. e – g Median normalized fold change of all sgRNAs targeting three essential TRAIL pathway components. A total of <t>100</t> sgRNAs are depicted for each gene. Enriched sgRNAs are colored in red , depleted sgRNAs in grey . The dashed line represents the median fold change of all sgRNAs of the corresponding gene
    160 Bp Single End Sequencing, supplied by Solexa, used in various techniques. Bioz Stars score: 82/100, based on 38 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/160 bp single end sequencing/product/Solexa
    Average 82 stars, based on 38 article reviews
    Price from $9.99 to $1999.99
    160 bp single end sequencing - by Bioz Stars, 2020-01
    82/100 stars
      Buy from Supplier

    80
    Illumina Inc bp single end rna sequencing data
    A pooled screen for functional validation of CLD. a The screening strategy in SW480 cells. In brief, a pool of mutant SW480 cells harboring 12,471 sgRNA designs against 408 genes was generated by lentiviral infection and antibiotic selection. Fourteen million cells per condition were then treated with PBS (control) or recombinant TRAIL (treatment) for a total of 12 days. Subsequently, the genomic DNA of the samples was extracted and sgRNA composition analyzed by next-generation sequencing ( NGS ). b Comparison of sgRNA sequence counts between two biological replicates demonstrates high reproducibility (Pearson correlation coefficient ~0.79). c Distribution of sgRNAs targeting positive pathway regulators ( CASP8 , CASP3 , FADD , BAX , BID , TNFRSF10A , TNFRSF10B ) in red , negative regulators ( XIAP , BCL2L1 ) in blue , and random, non-targeting sgRNAs in orange between TRAIL ( y-axis ) and PBS ( x-axis ) treated cell populations. d Scatter plot showing relative enrichment of genes ( y-axis ) with their corresponding p value ( x-axis ). Positive regulators are plotted in red , negative regulators in blue , and random, non-targeting sgRNAs in orange. P values were calculated by Wilcoxon rank sum test between 30 sgRNAs of one gene and 200 random, non-targeting sgRNAs. Log 2 fold change is calculated as median log 2 ratio between normalized sgRNA count of TRAIL- over PBS-treated populations. The vertical line marks a p value of 0.05. e – g Median normalized fold change of all sgRNAs targeting three essential TRAIL pathway components. A total of <t>100</t> sgRNAs are depicted for each gene. Enriched sgRNAs are colored in red , depleted sgRNAs in grey . The dashed line represents the median fold change of all sgRNAs of the corresponding gene
    Bp Single End Rna Sequencing Data, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 80/100, based on 5 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bp single end rna sequencing data/product/Illumina Inc
    Average 80 stars, based on 5 article reviews
    Price from $9.99 to $1999.99
    bp single end rna sequencing data - by Bioz Stars, 2020-01
    80/100 stars
      Buy from Supplier

    79
    Illumina Inc hiseq 2000 single end 110 bp sequencing
    A pooled screen for functional validation of CLD. a The screening strategy in SW480 cells. In brief, a pool of mutant SW480 cells harboring 12,471 sgRNA designs against 408 genes was generated by lentiviral infection and antibiotic selection. Fourteen million cells per condition were then treated with PBS (control) or recombinant TRAIL (treatment) for a total of 12 days. Subsequently, the genomic DNA of the samples was extracted and sgRNA composition analyzed by next-generation sequencing ( NGS ). b Comparison of sgRNA sequence counts between two biological replicates demonstrates high reproducibility (Pearson correlation coefficient ~0.79). c Distribution of sgRNAs targeting positive pathway regulators ( CASP8 , CASP3 , FADD , BAX , BID , TNFRSF10A , TNFRSF10B ) in red , negative regulators ( XIAP , BCL2L1 ) in blue , and random, non-targeting sgRNAs in orange between TRAIL ( y-axis ) and PBS ( x-axis ) treated cell populations. d Scatter plot showing relative enrichment of genes ( y-axis ) with their corresponding p value ( x-axis ). Positive regulators are plotted in red , negative regulators in blue , and random, non-targeting sgRNAs in orange. P values were calculated by Wilcoxon rank sum test between 30 sgRNAs of one gene and 200 random, non-targeting sgRNAs. Log 2 fold change is calculated as median log 2 ratio between normalized sgRNA count of TRAIL- over PBS-treated populations. The vertical line marks a p value of 0.05. e – g Median normalized fold change of all sgRNAs targeting three essential TRAIL pathway components. A total of <t>100</t> sgRNAs are depicted for each gene. Enriched sgRNAs are colored in red , depleted sgRNAs in grey . The dashed line represents the median fold change of all sgRNAs of the corresponding gene
    Hiseq 2000 Single End 110 Bp Sequencing, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 79/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hiseq 2000 single end 110 bp sequencing/product/Illumina Inc
    Average 79 stars, based on 6 article reviews
    Price from $9.99 to $1999.99
    hiseq 2000 single end 110 bp sequencing - by Bioz Stars, 2020-01
    79/100 stars
      Buy from Supplier

    79
    Illumina Inc hi seq2000 100 bp single end sequencing
    A pooled screen for functional validation of CLD. a The screening strategy in SW480 cells. In brief, a pool of mutant SW480 cells harboring 12,471 sgRNA designs against 408 genes was generated by lentiviral infection and antibiotic selection. Fourteen million cells per condition were then treated with PBS (control) or recombinant TRAIL (treatment) for a total of 12 days. Subsequently, the genomic DNA of the samples was extracted and sgRNA composition analyzed by next-generation sequencing ( NGS ). b Comparison of sgRNA sequence counts between two biological replicates demonstrates high reproducibility (Pearson correlation coefficient ~0.79). c Distribution of sgRNAs targeting positive pathway regulators ( CASP8 , CASP3 , FADD , BAX , BID , TNFRSF10A , TNFRSF10B ) in red , negative regulators ( XIAP , BCL2L1 ) in blue , and random, non-targeting sgRNAs in orange between TRAIL ( y-axis ) and PBS ( x-axis ) treated cell populations. d Scatter plot showing relative enrichment of genes ( y-axis ) with their corresponding p value ( x-axis ). Positive regulators are plotted in red , negative regulators in blue , and random, non-targeting sgRNAs in orange. P values were calculated by Wilcoxon rank sum test between 30 sgRNAs of one gene and 200 random, non-targeting sgRNAs. Log 2 fold change is calculated as median log 2 ratio between normalized sgRNA count of TRAIL- over PBS-treated populations. The vertical line marks a p value of 0.05. e – g Median normalized fold change of all sgRNAs targeting three essential TRAIL pathway components. A total of <t>100</t> sgRNAs are depicted for each gene. Enriched sgRNAs are colored in red , depleted sgRNAs in grey . The dashed line represents the median fold change of all sgRNAs of the corresponding gene
    Hi Seq2000 100 Bp Single End Sequencing, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 79/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hi seq2000 100 bp single end sequencing/product/Illumina Inc
    Average 79 stars, based on 6 article reviews
    Price from $9.99 to $1999.99
    hi seq2000 100 bp single end sequencing - by Bioz Stars, 2020-01
    79/100 stars
      Buy from Supplier

    79
    Illumina Inc hiseq 100 bp single end sequencing
    A pooled screen for functional validation of CLD. a The screening strategy in SW480 cells. In brief, a pool of mutant SW480 cells harboring 12,471 sgRNA designs against 408 genes was generated by lentiviral infection and antibiotic selection. Fourteen million cells per condition were then treated with PBS (control) or recombinant TRAIL (treatment) for a total of 12 days. Subsequently, the genomic DNA of the samples was extracted and sgRNA composition analyzed by next-generation sequencing ( NGS ). b Comparison of sgRNA sequence counts between two biological replicates demonstrates high reproducibility (Pearson correlation coefficient ~0.79). c Distribution of sgRNAs targeting positive pathway regulators ( CASP8 , CASP3 , FADD , BAX , BID , TNFRSF10A , TNFRSF10B ) in red , negative regulators ( XIAP , BCL2L1 ) in blue , and random, non-targeting sgRNAs in orange between TRAIL ( y-axis ) and PBS ( x-axis ) treated cell populations. d Scatter plot showing relative enrichment of genes ( y-axis ) with their corresponding p value ( x-axis ). Positive regulators are plotted in red , negative regulators in blue , and random, non-targeting sgRNAs in orange. P values were calculated by Wilcoxon rank sum test between 30 sgRNAs of one gene and 200 random, non-targeting sgRNAs. Log 2 fold change is calculated as median log 2 ratio between normalized sgRNA count of TRAIL- over PBS-treated populations. The vertical line marks a p value of 0.05. e – g Median normalized fold change of all sgRNAs targeting three essential TRAIL pathway components. A total of <t>100</t> sgRNAs are depicted for each gene. Enriched sgRNAs are colored in red , depleted sgRNAs in grey . The dashed line represents the median fold change of all sgRNAs of the corresponding gene
    Hiseq 100 Bp Single End Sequencing, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 79/100, based on 12 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hiseq 100 bp single end sequencing/product/Illumina Inc
    Average 79 stars, based on 12 article reviews
    Price from $9.99 to $1999.99
    hiseq 100 bp single end sequencing - by Bioz Stars, 2020-01
    79/100 stars
      Buy from Supplier

    77
    Illumina Inc hiseq2000 single end 100 bp dna sequencing
    A pooled screen for functional validation of CLD. a The screening strategy in SW480 cells. In brief, a pool of mutant SW480 cells harboring 12,471 sgRNA designs against 408 genes was generated by lentiviral infection and antibiotic selection. Fourteen million cells per condition were then treated with PBS (control) or recombinant TRAIL (treatment) for a total of 12 days. Subsequently, the genomic DNA of the samples was extracted and sgRNA composition analyzed by next-generation sequencing ( NGS ). b Comparison of sgRNA sequence counts between two biological replicates demonstrates high reproducibility (Pearson correlation coefficient ~0.79). c Distribution of sgRNAs targeting positive pathway regulators ( CASP8 , CASP3 , FADD , BAX , BID , TNFRSF10A , TNFRSF10B ) in red , negative regulators ( XIAP , BCL2L1 ) in blue , and random, non-targeting sgRNAs in orange between TRAIL ( y-axis ) and PBS ( x-axis ) treated cell populations. d Scatter plot showing relative enrichment of genes ( y-axis ) with their corresponding p value ( x-axis ). Positive regulators are plotted in red , negative regulators in blue , and random, non-targeting sgRNAs in orange. P values were calculated by Wilcoxon rank sum test between 30 sgRNAs of one gene and 200 random, non-targeting sgRNAs. Log 2 fold change is calculated as median log 2 ratio between normalized sgRNA count of TRAIL- over PBS-treated populations. The vertical line marks a p value of 0.05. e – g Median normalized fold change of all sgRNAs targeting three essential TRAIL pathway components. A total of <t>100</t> sgRNAs are depicted for each gene. Enriched sgRNAs are colored in red , depleted sgRNAs in grey . The dashed line represents the median fold change of all sgRNAs of the corresponding gene
    Hiseq2000 Single End 100 Bp Dna Sequencing, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 77/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hiseq2000 single end 100 bp dna sequencing/product/Illumina Inc
    Average 77 stars, based on 2 article reviews
    Price from $9.99 to $1999.99
    hiseq2000 single end 100 bp dna sequencing - by Bioz Stars, 2020-01
    77/100 stars
      Buy from Supplier

    77
    Illumina Inc 50 bp single end sequencing protocol
    A pooled screen for functional validation of CLD. a The screening strategy in SW480 cells. In brief, a pool of mutant SW480 cells harboring 12,471 sgRNA designs against 408 genes was generated by lentiviral infection and antibiotic selection. Fourteen million cells per condition were then treated with PBS (control) or recombinant TRAIL (treatment) for a total of 12 days. Subsequently, the genomic DNA of the samples was extracted and sgRNA composition analyzed by next-generation sequencing ( NGS ). b Comparison of sgRNA sequence counts between two biological replicates demonstrates high reproducibility (Pearson correlation coefficient ~0.79). c Distribution of sgRNAs targeting positive pathway regulators ( CASP8 , CASP3 , FADD , BAX , BID , TNFRSF10A , TNFRSF10B ) in red , negative regulators ( XIAP , BCL2L1 ) in blue , and random, non-targeting sgRNAs in orange between TRAIL ( y-axis ) and PBS ( x-axis ) treated cell populations. d Scatter plot showing relative enrichment of genes ( y-axis ) with their corresponding p value ( x-axis ). Positive regulators are plotted in red , negative regulators in blue , and random, non-targeting sgRNAs in orange. P values were calculated by Wilcoxon rank sum test between 30 sgRNAs of one gene and 200 random, non-targeting sgRNAs. Log 2 fold change is calculated as median log 2 ratio between normalized sgRNA count of TRAIL- over PBS-treated populations. The vertical line marks a p value of 0.05. e – g Median normalized fold change of all sgRNAs targeting three essential TRAIL pathway components. A total of <t>100</t> sgRNAs are depicted for each gene. Enriched sgRNAs are colored in red , depleted sgRNAs in grey . The dashed line represents the median fold change of all sgRNAs of the corresponding gene
    50 Bp Single End Sequencing Protocol, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 77/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/50 bp single end sequencing protocol/product/Illumina Inc
    Average 77 stars, based on 4 article reviews
    Price from $9.99 to $1999.99
    50 bp single end sequencing protocol - by Bioz Stars, 2020-01
    77/100 stars
      Buy from Supplier

    76
    Illumina Inc 101 bp single end rna sequencing
    A pooled screen for functional validation of CLD. a The screening strategy in SW480 cells. In brief, a pool of mutant SW480 cells harboring 12,471 sgRNA designs against 408 genes was generated by lentiviral infection and antibiotic selection. Fourteen million cells per condition were then treated with PBS (control) or recombinant TRAIL (treatment) for a total of 12 days. Subsequently, the genomic DNA of the samples was extracted and sgRNA composition analyzed by next-generation sequencing ( NGS ). b Comparison of sgRNA sequence counts between two biological replicates demonstrates high reproducibility (Pearson correlation coefficient ~0.79). c Distribution of sgRNAs targeting positive pathway regulators ( CASP8 , CASP3 , FADD , BAX , BID , TNFRSF10A , TNFRSF10B ) in red , negative regulators ( XIAP , BCL2L1 ) in blue , and random, non-targeting sgRNAs in orange between TRAIL ( y-axis ) and PBS ( x-axis ) treated cell populations. d Scatter plot showing relative enrichment of genes ( y-axis ) with their corresponding p value ( x-axis ). Positive regulators are plotted in red , negative regulators in blue , and random, non-targeting sgRNAs in orange. P values were calculated by Wilcoxon rank sum test between 30 sgRNAs of one gene and 200 random, non-targeting sgRNAs. Log 2 fold change is calculated as median log 2 ratio between normalized sgRNA count of TRAIL- over PBS-treated populations. The vertical line marks a p value of 0.05. e – g Median normalized fold change of all sgRNAs targeting three essential TRAIL pathway components. A total of <t>100</t> sgRNAs are depicted for each gene. Enriched sgRNAs are colored in red , depleted sgRNAs in grey . The dashed line represents the median fold change of all sgRNAs of the corresponding gene
    101 Bp Single End Rna Sequencing, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 76/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/101 bp single end rna sequencing/product/Illumina Inc
    Average 76 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    101 bp single end rna sequencing - by Bioz Stars, 2020-01
    76/100 stars
      Buy from Supplier

    86
    Illumina Inc nextseq 500 sequencer 75 bp single end
    A pooled screen for functional validation of CLD. a The screening strategy in SW480 cells. In brief, a pool of mutant SW480 cells harboring 12,471 sgRNA designs against 408 genes was generated by lentiviral infection and antibiotic selection. Fourteen million cells per condition were then treated with PBS (control) or recombinant TRAIL (treatment) for a total of 12 days. Subsequently, the genomic DNA of the samples was extracted and sgRNA composition analyzed by next-generation sequencing ( NGS ). b Comparison of sgRNA sequence counts between two biological replicates demonstrates high reproducibility (Pearson correlation coefficient ~0.79). c Distribution of sgRNAs targeting positive pathway regulators ( CASP8 , CASP3 , FADD , BAX , BID , TNFRSF10A , TNFRSF10B ) in red , negative regulators ( XIAP , BCL2L1 ) in blue , and random, non-targeting sgRNAs in orange between TRAIL ( y-axis ) and PBS ( x-axis ) treated cell populations. d Scatter plot showing relative enrichment of genes ( y-axis ) with their corresponding p value ( x-axis ). Positive regulators are plotted in red , negative regulators in blue , and random, non-targeting sgRNAs in orange. P values were calculated by Wilcoxon rank sum test between 30 sgRNAs of one gene and 200 random, non-targeting sgRNAs. Log 2 fold change is calculated as median log 2 ratio between normalized sgRNA count of TRAIL- over PBS-treated populations. The vertical line marks a p value of 0.05. e – g Median normalized fold change of all sgRNAs targeting three essential TRAIL pathway components. A total of <t>100</t> sgRNAs are depicted for each gene. Enriched sgRNAs are colored in red , depleted sgRNAs in grey . The dashed line represents the median fold change of all sgRNAs of the corresponding gene
    Nextseq 500 Sequencer 75 Bp Single End, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 86/100, based on 10 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nextseq 500 sequencer 75 bp single end/product/Illumina Inc
    Average 86 stars, based on 10 article reviews
    Price from $9.99 to $1999.99
    nextseq 500 sequencer 75 bp single end - by Bioz Stars, 2020-01
    86/100 stars
      Buy from Supplier

    Image Search Results


    A pooled screen for functional validation of CLD. a The screening strategy in SW480 cells. In brief, a pool of mutant SW480 cells harboring 12,471 sgRNA designs against 408 genes was generated by lentiviral infection and antibiotic selection. Fourteen million cells per condition were then treated with PBS (control) or recombinant TRAIL (treatment) for a total of 12 days. Subsequently, the genomic DNA of the samples was extracted and sgRNA composition analyzed by next-generation sequencing ( NGS ). b Comparison of sgRNA sequence counts between two biological replicates demonstrates high reproducibility (Pearson correlation coefficient ~0.79). c Distribution of sgRNAs targeting positive pathway regulators ( CASP8 , CASP3 , FADD , BAX , BID , TNFRSF10A , TNFRSF10B ) in red , negative regulators ( XIAP , BCL2L1 ) in blue , and random, non-targeting sgRNAs in orange between TRAIL ( y-axis ) and PBS ( x-axis ) treated cell populations. d Scatter plot showing relative enrichment of genes ( y-axis ) with their corresponding p value ( x-axis ). Positive regulators are plotted in red , negative regulators in blue , and random, non-targeting sgRNAs in orange. P values were calculated by Wilcoxon rank sum test between 30 sgRNAs of one gene and 200 random, non-targeting sgRNAs. Log 2 fold change is calculated as median log 2 ratio between normalized sgRNA count of TRAIL- over PBS-treated populations. The vertical line marks a p value of 0.05. e – g Median normalized fold change of all sgRNAs targeting three essential TRAIL pathway components. A total of 100 sgRNAs are depicted for each gene. Enriched sgRNAs are colored in red , depleted sgRNAs in grey . The dashed line represents the median fold change of all sgRNAs of the corresponding gene

    Journal: Genome Biology

    Article Title: CRISPR library designer (CLD): software for multispecies design of single guide RNA libraries

    doi: 10.1186/s13059-016-0915-2

    Figure Lengend Snippet: A pooled screen for functional validation of CLD. a The screening strategy in SW480 cells. In brief, a pool of mutant SW480 cells harboring 12,471 sgRNA designs against 408 genes was generated by lentiviral infection and antibiotic selection. Fourteen million cells per condition were then treated with PBS (control) or recombinant TRAIL (treatment) for a total of 12 days. Subsequently, the genomic DNA of the samples was extracted and sgRNA composition analyzed by next-generation sequencing ( NGS ). b Comparison of sgRNA sequence counts between two biological replicates demonstrates high reproducibility (Pearson correlation coefficient ~0.79). c Distribution of sgRNAs targeting positive pathway regulators ( CASP8 , CASP3 , FADD , BAX , BID , TNFRSF10A , TNFRSF10B ) in red , negative regulators ( XIAP , BCL2L1 ) in blue , and random, non-targeting sgRNAs in orange between TRAIL ( y-axis ) and PBS ( x-axis ) treated cell populations. d Scatter plot showing relative enrichment of genes ( y-axis ) with their corresponding p value ( x-axis ). Positive regulators are plotted in red , negative regulators in blue , and random, non-targeting sgRNAs in orange. P values were calculated by Wilcoxon rank sum test between 30 sgRNAs of one gene and 200 random, non-targeting sgRNAs. Log 2 fold change is calculated as median log 2 ratio between normalized sgRNA count of TRAIL- over PBS-treated populations. The vertical line marks a p value of 0.05. e – g Median normalized fold change of all sgRNAs targeting three essential TRAIL pathway components. A total of 100 sgRNAs are depicted for each gene. Enriched sgRNAs are colored in red , depleted sgRNAs in grey . The dashed line represents the median fold change of all sgRNAs of the corresponding gene

    Article Snippet: The purified libraries were controlled for correct size using DNA High Sensitivity Assay on a BioAnalyzer 2100 (Agilent) and then sequenced on a MiSeq (Illumina) by 100-bp single-end sequencing and addition of 20 % PhiX Control v3 (Illumina) at a concentration of 8 pM.

    Techniques: Functional Assay, Mutagenesis, Generated, Infection, Selection, Recombinant, Next-Generation Sequencing, Sequencing